Therapeutic Areas in Ophthalmology ace

Uveitis

Inquiry

Accelerating Uveitis Research

About Uveitis

What is Uveitis?

Uveitis refers to various intraocular inflammatory diseases that occur in the uvea (iris, ciliary body, choroid) and its adjacent structures (including the cornea, vitreous body, retina, and optic nerve). If left undiagnosed and treated, it can lead to cataracts, glaucoma, corneal lesions, macular edema, and even permanent vision loss. Uveitis can be divided into non-infectious uveitis and infectious uveitis. Based on the anatomical site of inflammation, noninfectious uveitis is further divided into anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Anterior uveitis is an inflammatory disease of the ciliary body and iris that can be diagnosed and treated early. Intermediate uveitis is associated with vitreous inflammation. Posterior uveitis involves the retina and choroid and is the most threatening to vision. In addition, uveal inflammatory lesions without specific etiology and systemic diseases can only involve the eyes, and may also be related to systemic autoimmune diseases, including Behcet's disease, rheumatic diseases, sarcoidosis, etc.

Fig. 1. Classification of uveitis based on anatomic sites. (Wu X, et al., 2022)

Current Clinical Trials

In recent years, the treatment of infectious uveitis has focused on the causative agent. In non-infectious uveitis, systemic corticosteroids are the most extensive treatment option. Table 1 lists some of the active phase 1 to 4 uveitis trials on ClinicalTrials.gov.

Tab1. Current clinical trials in uveitis. (Hojjatie RA, et al., 2024)

Clinical trial	Research institute	Phase
The Minocycline for Chronic Autoimmune Uveitis	Sun Yat-Sen University	Phase 1
The Study of Izokibep in Noninfectious, Intermediate-, Posterior-, or Panuveitis	Acelyrin Inc	Phase 2
The Effectivity of Antituberculosis Therapy in Idiopathic Uveitis with Positive Interferon Gamma Release Assay (IGRA)	Fakultas Kedokteran University	Phase 2
Abatacept in Patients with Birdshot HLA A29 Uveitis	Ziekehuizen Leuven University	Phase 2
Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis	Sun Yat-Sen University	Phase 2
Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)	Stanford University and Santen Inc	Phase 2
A Study of Brepocitinib in Adults with Active Noninfectious Nonanterior Uveitis (NEPTUNE)	Priovant Therapeutics	Phase 2
A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association with Prednisone for the Treatment of Noninfectious Severe Uveitis (NISU)	Dijon University Hospital	Phase 2
Reduction or Discontinuation of TNF-α Inhibitor in Noninfectious Uveitis Patients	Sun Yat-Sen University	Phase 2
Golimumab for the Treatment of Refractory Behcet’s Uveitis	Peking Union Medical College Hospital	Phase 2
Adalimumab vs Conventional Immunosuppression for Uveitis Trial (ADVISE)	Johns Hopkins Center for Clinical Trials and Evidence Synthesis	Phase 3
Efficacy, Safety, and Costs of Methotrexate, Adalimumab, or Their Combination in Noninfectious Nonanterior Uveitis (Co-THEIA)	Hospital San Carlos	Phase 3
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old with Active JIA-associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	Eli Lilly and Company	Phase 3
A Study of TRS01 in Subjects with Active Noninfectious Anterior Uveitis Including Subjects with Uveitic Glaucoma	Tarsier	Phase 3
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI),	EyePoint Pharmaceuticals	Phase 3
The Use of 2 Yutiq vs Sham for Treatment of Chronic Noninfectious Intraocular Inflammation Affecting the Posterior Segment (TYNI)	Texas Retina Associates and Eye Point Pharmaceuticals	Phase 3
Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes (STACCATO)	University of California	Phase 3
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis (Limit-JIA)	Duke University	Phase 3
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Noninfectious Posterior Segment Uveitis	EyePoint Pharmaceuticals	Phase 4
Adalimumab in JIA-associated Uveitis Stopping Trial (ADJUST)	University of California	Phase 4
Biologic Therapy in Pediatric JIA Uveitis	Kasr El Aini Hospital	Phase 4
A Clinical Trial of Infliximab for Childhood Uveitis	Tianjin Medical University	Phase 4
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Noninfectious Intermediate, Posterior, or Panuveitis	AbbVie	Phase 4
The Efficacy and Safety of Adalimumab in Noninfectious Anterior Pediatric Uveitis with Peripheral Vascular Leakage	Peking Union Medical College Hospital	Phase 4
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis/Endotheliitis	Singapore National Eye Centre	Phase 4
The Ozurdex Monotherapy Trial (OM)	Ottawa Hospital Research Institute	Phase 4

One-Stop Preclinical Uveitis Studies Solutions

With remarkable advances in the understanding and diagnosis of uveitis, more and more treatment options are being investigated, and the future of uveitis treatment looks bright. Recent and ongoing research is leading to more targeted treatments that will substantially improve uveitis patient outcomes.

As an industry-leading comprehensive contract research organization (CRO), Ace Therapeutics focuses on the health of ocular diseases and improves ocular diseases by helping customers provide drug discovery and preclinical research solutions. Our support staff averages decades of experience in preclinical ophthalmology research for pharmaceutical companies, biotech companies, and large CROs, who help customers around the world deal with each stage of preclinical drug development. Our one-stop solutions cover the development of ocular disease models, in vivo ocular pharmacodynamic studies, ocular tolerance and safety studies, early pilot studies, and proof-of-concept and bioanalytical levels. All of our projects are customizable and flexible, which allows us to fully understand our clients' needs and how to meet them.

At Ace Therapeutics, our expert team supports all aspects of your uveitis research. We have established multi-species uveitis models, including experimental autoimmune uveoretinitis (EAU) and anterior uveitis models, to help you understand the pathology of this disease and explore promising therapies. Our service scope covers the whole process from lead compound discovery to the implementation of preclinical GLP projects. With years of experience in uveitis drug development and model building, we are happy to provide you with a series of preclinical services for uveitis ophthalmic product development, including anterior uveitis model development, mechanism research, and evaluation of new therapies.

References

Wu X, Tao M, Zhu L, et al. Pathogenesis and current therapies for non-infectious uveitis. Clin Exp Med. 2022.
Hojjatie RA, Arepalli S. UVEITIS CORNER: Update on Topical and Local Steroid Treatments for Uveitis. Retinal Physician. 2024

Diabetic Retinopathy DR

For Research Use Only.

Get in Touch